Expert Pitch
Virginia Tech

Biostatistics expert: ‘We’re not testing as much as we should be’ for COVID-19's spread

30-Mar-2020 8:25 AM EDT, by Virginia Tech

A Virginia Tech professor who specializes in statistical modeling and disease surveillance says the United States has to do a better job of testing for the novel coronavirus if the country is to be successful in mitigating the virus’ spread.

“We don’t know what we don’t know,” said Ron Fricker, a professor of statistics in the Virginia Tech College of Science. “COVID-19 is here but we don’t have a good estimate of how widespread it is in the general population. That’s a real challenge. You can’t contain a virus if you don’t know where it is. It’s like trying to drive your car using only the rearview mirror.”   

Prior to his work at Virginia Tech, Fricker was senior statistician at the RAND Corporation and the associate director of the RAND National Security Research Division, a unit within the RAND Corporation responsible for conducting research and analysis on complex national defense policy and strategy problems. 

Having reliable data about COVID-19 incidence in the general population is critical and a necessary part of slowing the rate of infections in a given area, he said.

“Key to combatting and containing the virus is understanding how it is affecting people, including its morbidity and mortality; how it is spreading between people; and tracking those who may be infected so that we can most effectively try to control the outbreak,” Fricker said. “All of those tasks, and more, depend on good data and the appropriate use of statistical methods.” 

Fricker noted that several current outbreaks in the country — including in California, Washington state, and New York City — provide crucial data about the coronavirus’ apparent spread. But owing to the relatively small number of tests that have been performed across the U.S., there’s still much more to learn about how the pathogen is transmitted.

“This is a highly contagious, highly transmissible disease,” Fricker said. “It’s not just New York. It’s not just Washington state. It is in many more places across the U.S. and we just don’t know it.”

 [More: Find additional Virginia Tech expertise related to COVID-19 here.] 

The fact that the novel coronavirus evidently started in China and initially spread elsewhere means the U.S. can learn from what's worked and what hasn’t in other countries, Fricker said. He cited South Korea and Germany as examples of countries which have used widespread testing very effectively to flatten the curve, a phrase now part of the modern zeitgeist which refers to attempts to have fewer people infected at one time, thereby preventing a surge that could inundate healthcare systems and potentially result in far more deaths.

“If we were to test more widely as South Korea has, we could make targeted actions much more accurately,” Fricker said. “We can understand the progress and estimate roughly what’s going to happen in the U.S. based on the world. What we can't do is accurately model at the regional or county level and create further projections.”

He added: “There’s little unique about the U.S. except for the fact we’re not testing as much as we should be.”

Like many experts who’ve spoken publicly or published early research, Fricker said he believes the virus has spread much further than current testing reveals.

“If you asked me right now what the prevalence of COVID-19 is in a given county, the answer is we don’t know,” he said. 

Fricker said the models being developed by those in academia and government will inherently improve as time goes on and more variables can be quantified.

“If the goal is to understand how it spreads, you need to understand the science behind it,” he said, noting that early research into how the coronavirus is transmitted person-to-person, how long it remains on surfaces, and other details will all help bring projections into focus. “All those kinds of things we have some information on, and we can use them to at least create rough projections.”

About Fricker

Ron Fricker is a professor of statistics at Virginia Tech with research focused on the performance of various statistical methods for use in disease surveillance, and statistical process control methodologies more generally. 

He is the co-author of "Monitoring the Health of Populations by Tracking Disease Outbreaks: Saving Humanity from the Next Plague,” which was published last month. So timely is the book that publication was briefly halted for numerical updates of those infected by the novel coronavirus. He is also the author of other works focusing on statistical methods for biosurveillance.

“We were motivated to write the latest book because the work of public health officials often critically depends on the use of statistical methods to help discern whether an outbreak may be occurring and, if there is sufficient evidence of an outbreak, then to locate and track it,” Fricker said. “With the recent outbreaks of diseases such as swine and bird flu, Ebola, and COVID-19, the role that epidemiologists and biostatisticians play is more important than ever.”  View his bio.

Our studio

Finding reliable experts for media interviews is especially important during this difficult time. Virginia Tech's television and radio studios can broadcast live HD audio and video to networks, news outlets, and affiliates interviewing Virginia Tech faculty and staff. The university does not charge for use of its studios. Video is transmitted by LTN Global Communications; Skype, FaceTime, or similar products; or file sharing (Dropbox, Google Drive, We-Transfer, etc.). Radio interviews can be transmitted by ISDN, Comrex, phone, smartphone recording, or file sharing.




Filters close

Showing results

110 of 2539
Released: 13-Jul-2020 4:05 PM EDT
OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available
Organization for Associate Degree Nursing (OADN)

OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 3:05 PM EDT
Asymptomatic Transmission and Reinfection of COVID: Live Event for July 16, 2PM EDT
Newswise

Emerging data shows more risk of asymptomatic transmission and reinfection with COVID than previously thought. Experts will discuss these findings and what are the implications for managing the pandemic. Media are invited to attend and ask questions.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.


Showing results

110 of 2539

close
2.32976